

1FW




PATENT
ATTORNEY DOCKET NO. 50164/026005

Certificate of Mailing: Date of Deposit: December 20, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Seth Kellogg
Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jost-Price et al.	Confirmation No.:	6701
Serial No.:	10/777,517	Art Unit:	1614
Filed:	February 12, 2004	Examiner:	Michel Graffeo
Customer No.:	21559		
Title:	METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 10/670,488, which was filed on September 24, 2003. The following references were submitted to and/or cited by the Office in the prior application and, therefore, copies of these references are not provided for this application:

WO 91/02527 A1;

WO 93/22685 A1;

WO 95/31722 A1;

WO 97/10815 A1;

WO 98/02169 A1;

WO 99/01121 A1;

WO 99/59598 A1;

WO 00/51592 A1;

WO 00/64441 A2;

WO 00/66522 A1;

WO 01/11334 A2;

WO 02/078643 A2;

WO 02/085297 A2;

WO 02/43652 A2;

WO 03/002129 A1;

WO 03/006026 A1;

WO 04/004734 A1;

Allan et al., *Cancer Chemother. Pharmacol.* 18(1):86-87 (1986);

Ardid and Guilbaud, *Pain* 49(2):279-287 (1992);

Arnold et al., *Am. J. Med.* 112(3):191-197 (2002);

Ash et al., *Rheumatology* 38(10):959-967 (1999);

Barden, *J. Psychiatry Neurosci.* 24(1):25-39 (1999);

Beers et al., Merck Manual of Medical Information, 2nd Ed., Merck Research Laboratories: Whitehouse Station, NJ, pp. 1-7 (2003);

Berberian et al., *Int. J. Dermatol.* 38(2):145-148 (1999);

Bianchi et al., *Inflamm. Res.* 44:466-469 (1995);

Bird and Broggini, *J. Rheumatol.* 27:2791-2797 (2000);

Bonuccelli et al., *Cephalalgia* 16(3):197-200 (1996);

Budziszewska et al., *Br. J. Pharmacol.* 130:1385-1393 (2000);

Calvo et al., *Int. J. Clin. Pharmacol. Ther. Toxicol.* 23(4):180-185 (1985);

Cantini et al., *Minerva Med.* 85(3):97-100 (1994);

Carelli et al., *Int. J. Pharmaceutics* 179:73-83 (1999);

Castanon et al., *Brain Behavior Immun.* 16:569-574 (2002);

Chan and Lee, *Pharmacol. Res. Comm.* 17(7):619-632 (1985);

Chuck et al., *Rheumatology* 39:1425-1426 (2000);

Clark, Johns Hopkins Arthritis website: <http://www.hopkins-arthritis.som.jhmi.edu/mngmnt/depression.html>;

Clouse et al., *Aliment Pharmacol. Ther.* 8(4):409-416 (1994);

Coupet et al., *Brain Research* 116:177-180 (1976);

D'Arcy et al., *J. Pharm. Sci.* 60(7):1028-1033 (1971);

Dessein et al., *Rheumatology* 38(12):1304-1305 (1999);

Didonato et al., *Am. J. Respir. Crit. Care Med.* 154:S11-S15 (1996);

Dinan et al., *Acta Psychiatr. Scand.* 95(1):58-61 (1997);

Drake and Millikan, *Arch. Dermatol.* 131(12):1403-1408 (1995);

Drake et al., *J. Am. Acad. Dermatol.* 41(2):209-214 (1999);

el-Mahdy et al., *J. Pharm. Pharmacol.* 42(7):522-524 (1990);

Ehrenstein, *Br. J. Rheumatol.* 34(6):580-581 (1995);

Esposito et al., *Pharm. Dev. Technol.* 5(2):267-278 (2000);

Fishbain, *Ann. Med.* 32:305-316 (2000);

Fowler et al., *Curr. Med. Res. Opin.* 5(3):241-246 (1977);

Frank et al., *J. Rheumatol.* 15(11):1632-1638 (1988);

Godefroy et al., *Pain* 25:233-244 (1986);

Goldenberg et al., *Arthritis Rheum.* 39(11):1852-1859 (1996);

Goodnick et al., *Psychopharmacol. Bull.* 33(2):261-264 (1997);

Gruber et al., *Psychiatr. Clin. North Am.* 19(2):351-369 (1996);

Gupta et al., *Arch. Dermatol.* 123(5):647-652 (1987);

Gupta and Gupta, *J. Eur. Acad. Dermatol. Venereol.* 15(6):512-518 (2001);

Hammad and Müller, *Eur. J. Pharm. Biopharm.* 46:361-367 (1998);

Healey and Wilske, *J. Rheumatol.* 18(5):641-642 (1991);

Hinze-Selch et al., *Neuropsychopharmacology* 23(1):13-19 (2000);

Holsboer, *Neuropsychopharmacology* 23(5):477-501 (2000);

Inouye et al., *Drug Des. Deliv.* 1:297-305 (1987);

Jett et al., *Pain* 69(1-2):161-169 (1997);

Johnson, *J. Fam. Pract.* 44(2):128-130 (1997);

Jue et al., *Drugs* 24:1-23 (1982);

Karlsten and Gordh, *Drugs Aging* 11(5):398-412 (1997);

Kirwan and Lim, *Drugs Aging* 8(3):157-161 (1996);

Kirwan, *Rheum. Dis. Clin. North Am.* 27(2):389-403 (2001);

Kitamori and Makino, *J. Pharm. Pharmacol.* 31:505-507 (1979);

Koh et al., *J. Rheumatol.* 24(11):2158-2161 (1997);

Kristensen, *Eur. J. Clin. Pharmacol.* 28:693-696 (1985);

Kubera et al., *Pol. J. Pharmacol.* 52(3):229-235 (2000);

Kubera et al., *J. Clin. Psychopharmacol.* 21(2):199-206 (2001);

Lanquillon et al., *Neuropsychopharmacology* 22(4):370-379 (2000);

Lee and Chan, *Eur. J. Pharmacol.* 106(2):255-262 (1985);

Lydiard and Gelenberg, *Pharmacotherapy* 1(3):163-178 (1981);

Macfarlane et al., *Curr. Med. Res. Opin.* 10(2):89-93 (1986);

MacNeill and Dick, *J. Int. Med. Res.* 4(2 Suppl):23-27 (1976);

Maes et al., *Psychol. Med.* 28(4):957-965 (1998);

Maes, Cytokines, Stress, and Depression, Dantzer et al. (Ed.), Plenum Publishers, NY, pp. 25-46 (1999);

Maes et al., *Neuropsychopharmacology* 20(4):370-379 (1999);

Maes et al., *Eur. Neuropsychopharmacol.* 10:119-124 (2000);

Magni, *Drugs* 42(5):730-748 (1991);

Martelli et al., *Eur. J. Pharmacol.* 2(3):229-233 (1967);

Mastaglia, *Drugs* 24:304-321 (1982);

McBride et al., *South. Med. J.* 62:307-314 (1969);

McLain, *South. Med. J.* 94(9):893-895 (2001);

Michelson et al., *Agents Actions* 42:25-28 (1994);

Morris, *J. Rheumatol.* 24(4):803-804 (1997);

Okugawa et al., *J. Neuroendocrinol.* 11:887-895 (1999);

Papp et al., *Am. J. Psychiatry* 152(10):1531 (1995);

Pariante et al., *Mol. Pharmacol.* 52:571-581 (1997);

Petitto et al., *Psychosomatics* 33(3):338-341 (1992);

Pfeiffer, *Geriatrics* 37(2):67-69, 73, 76 (1982);

Pullar, *Br. J. Rheumatol.* 30(4):311 (1991);

Puttini et al., *J. Int. Med. Res.* 16(5):331-337 (1988);

Rani et al., *Anesth. Analg.* 83:371-375 (1996);

Rao et al., *J. Pharm. Sci.* 90(7):807-816 (2001);

Russell and Ramos-Remus, *J. Rheumatol.* 24:803-804 (1997);

Sabroe et al., *Br. J. Dermatol.* 137(3):386-390 (1997);

Schreiber et al., *Eur. Neuropsychopharmacol.* 6(4):281-284 (1996);

Scott et al., *Pharmacotherapy* 19(2):236-239 (1999);

Shelanski et al., *Int. J. Dermatol.* 35(2):137-140 (1996);
 Slaughter et al., *Psychosomatics* 43(1):36-41 (2002);
 Slotkin et al., *Biol. Psychiatry* 40(7):576-584 (1996);
 Smith and Correlli, *Ann. Pharmacother.* 31(5):633-635 (1997);
 Swinson, *J. Rheumatol.* 17:277 (1990);
 Tangri et al., *Biochem. Pharmacol.* 15:825-831 (1966);
 Tasset and Pesce, *J. Anal. Toxicol.* 8(3):124-128 (1984);
 Thorpe and Marchant-Williams, *Med. J. Austral.* 1(8):264-266 (1974);
 Uekama et al., *J. Pharm. Dyn.* 6:124-127 (1983);
 van den Berg et al., *Ann. Rheum. Dis.* 58(Suppl I):I40-I48 (1999);
 Van Laethem et al., *Cell. Mol. Life Sci.* 58:1599-1606 (2001);
 Vedder et al., *J. Psych. Res.* 33:303-308 (1999);
 Williams, *Br. J. Rheumatol.* 33:603-604 (1994);
 Wolfe et al., *Scand. J. Rheumatol.* 23(5):255-259 (1994);
 Xia et al., *Immunopharmacology* 34(1):27-37 (1996);
 Yano et al., *J. Pharm. Sci.* 90(4):493-503 (2001);
 Yano et al., *J. Control. Rel.* 79(1-3):103-112 (2002);
 Yaron et al., *Arth. Rheumatol.* 42(12):2561-2568 (1999);
 Yocum, *Sem. Arth. Rheumat.* 29(1):27-35 (1999);
 Yohannes et al., *Int. J. Geriatr. Psychiatry* 16(5):451-454 (2001); and
 International Search Report for WO 04/030618.


Applicants direct the Examiner to co-pending U.S. Patent Application Nos. 10/670,488 and 10/947,455. In each case, a non-final Office Action has issued.

This statement is being filed before the receipt of a first Office Action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No.
03-2095.

Respectfully submitted,

Date:

12/20/07 

Michael J. Belliveau, Ph.D.
Reg. No. 52,608

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045